BRAINTREE, Mass., July 23, 2014 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Charles J. Dockendorff was elected to the Board of Directors at the Company's Annual Meeting of Stockholders today. Mr. Dockendorff, age 59, is Executive Vice President and Chief Financial Officer with Covidien PLC, a position he has held since 1995. He is responsible for Covidien's financial management activities including corporate accounting, tax, treasury, financial planning, investor relations, internal audit and information services, and he oversees the financial leadership of Covidien's three business segments.
Mr. Dockendorff joined Kendall Healthcare Products Company, the foundation of Covidien formerly known as Tyco Healthcare, in 1989 as Controller and he was named Vice President and Controller in 1994. He was appointed CFO of Covidien 1995 and held that position throughout the company's growth from $600 million in revenue to a diverse $10 billion healthcare products leader.
Before joining Covidien and its predecessors, Mr. Dockendorff was CFO, Vice President of Finance and Treasurer of Epsco, Inc. and the CFO of Infrared Industries, Inc. His early career included accounting positions with Arthur Young & Company (now Ernst & Young) and General Motors Corporation. He is a CPA and has a Bachelor's degree in Business Administration/Accounting from the University of Massachusetts and a Master of Science degree in Finance from Bentley College.
Richard J. Meelia, Chairman of Haemonetics' Board of Directors commented, "Chuck is a highly-respected healthcare industry leader. He brings an extensive financial management and planning background to our board, along with considerable experience with one of the world's premier healthcare products companies. His contributions will help to guide the Company as it seeks to grow market share and provide industry leading returns to shareholders."
"Blood management is a key element of the health care continuum globally, as patient care advances and the focus on reducing costs continues to be a priority. Haemonetics is very well positioned with solutions to help our collection and hospital customers address these opportunities," said Mr. Dockendorff. "I look forward to joining the Board of Directors and serving the Company's shareholders."
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613
SOURCE Haemonetics Corporation